Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease.

1. Hexa Reports
Market Research Reports and Insightful Company Profiles
Orencia (abatacept) (Rheumatoid Arthritis) Global Share and
Size, Growth and Overview, Forecast and Market Analysis to
2023
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM covered in this report (US, France,
Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to
just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and
symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly
changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK
inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as
extremely effective therapies for RA, the market is extremely competitive for new entrants and will
undergo further pressure as biosimilars are approved and launch.
BMS' Orencia (abatacept) is a soluble biologic, and structurally, is a fully-humanized fusion protein of the
extracellular domain of the human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with the Fc
domain of human IgG1. The drug functions by preventing T-cell activation. The co-stimulatory molecules
CD80 and CD86 are able to bind to CTLA-4, which typically blocks T-cell activation, or to CD28, which

2. Hexa Reports
Market Research Reports and Insightful Company Profiles
activates T cells. Because CTLA-4 has a higher affinity for CD80 and CD86, Orencia is able to block the
activation of T cells by competing with CD28 for binding to CD80/CD86.
Browse Detail Report With TOC @ http://www.hexareports.com/report/orencia-abatacept-
rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details
Scope
Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Orencia (Abatacept) including product description, safety and efficacy profiles
as well as a SWOT analysis.
Sales forecast for Orencia (Abatacept) for the top 9 countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and India.
Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return.
Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid
Arthritis.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential.
Make more informed business decisions from insightful and in-depth analysis of Orencia (Abatacept)
performance.
Obtain sales forecast for Orencia (Abatacept) from 2013-2023 in top 9 countries (the US, France,
Germany, Italy, Spain, the UK and Japan, Australia and India).
Table Of Content
Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
Request A Sample copy of This Report @ http://www.hexareports.com/sample/42258
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13

3. Hexa Reports
Market Research Reports and Insightful Company Profiles
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Diagnosis 20
4.1.2 Treatment Guidelines 22
4.1.3 Leading Prescribed Drugs for the Treatment of RA 31
4.1.4 Clinical Practice 33
5 Competitive Assessment 38
5.1 Overview 38
6 Orencia (abatacept) 40
6.1 Overview 40
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 44
6.5 Forecast 45
Browse Full Report @ http://www.hexareports.com/report/orencia-abatacept-rheumatoid-arthritis-
forecast-and-market-analysis-to-2023/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/